Similarly, an exploratory analysis of integrated RNA sequencing (RNA-seq) and targeted somatic variant analysis from tumor samples of the IMmotion151 study (comparing atezolizumab plus bevacizumab to sunitinib) defined seven clusters of RCC associated with a different response to ICI-based combinations and VEGFR-TKI alone. This evidence concerns the gene KDR and renal cell carcinoma.